Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Baxter International Inc. reported second-quarter 2026 sales of $2.96 billion, up 5% on both a reported and organic basis, with growth across all segments and geographies. GAAP net income from continuing operations was $135 million, or $0.26 per diluted share, while adjusted diluted EPS from continuing operations was $0.56, down 5% from the prior-year quarter. Segment sales reached $2,076 million in Medical Products & Therapies and $801 million in Healthcare Systems & Technologies. Free cash flow from continuing operations was $181 million in the quarter and $257 million year-to-date.
Management noted that results benefited from both operating performance and a $0.11 per share IEEPA tariff refund. Reflecting this performance, the company raised its full-year 2026 outlook to reported sales growth of 3%–4%, organic sales growth of 2%–3%, and adjusted diluted EPS from continuing operations of $1.95–$2.15. The board also declared a quarterly cash dividend of $0.01 per share, payable October 1, 2026 to shareholders of record on August 28, 2026.
Baxter International Inc. reorganized its reporting structure into two segments, Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST), effective for the quarter ended June 30, 2026. The former Pharmaceuticals segment is now included in the Infusion Therapies & Platforms division within MPT, and certain manufacturing-related sales previously in Other are reclassified into that division. Remaining Other sales primarily reflect transactions with Vantive Health LLC under the Kidney Care manufacturing and supply agreement. Shared corporate expenses will now be partially left unallocated rather than fully assigned to segments.
The company furnished unaudited recast segment and product-category data for 2024–2025 and recent quarters to align history with this model. For 2025, Total Baxter net sales were $11,244 million, a reported increase of 6% and 3% operational sales growth. MPT generated $7,843 million in net sales and HST $3,071 million. Despite segment operating income of $2,246 million in 2025, after corporate items, amortization, impairments, optimization, separation and hurricane costs, total operating income was a loss of $308 million, and loss from continuing operations before income taxes was $505 million.
For the quarter ended March 31, 2026, Total Baxter net sales were $2,701 million, up 3% year over year, while organic sales declined 1%. Baxter explains non-GAAP operational and organic sales growth as measures that exclude the Kidney Care agreement’s impact, certain exits, acquisitions or divestitures, and foreign-exchange effects, to better isolate underlying performance trends.
Baxter International Inc. files Amendment No. 2 to Schedule 13G/A reporting 52,972,914.27 shares of Common Stock beneficially owned, representing 10.3% of the class. The filing names FMR LLC as the holder with sole dispositive power for that amount and notes related power-of-attorney exhibits.
Zielinski Anita A reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. reported that senior vice president and interim CFO Anita A. Zielinski received a one-time special grant of 13,426 shares of common stock as a restricted stock unit award in connection with her additional duties. The award was granted at no cash cost to her and is scheduled to vest on the third anniversary of the grant date, subject to vesting requirements under Baxter’s Second Amended and Restated 2021 Incentive Plan. Following this equity grant and automatic reinvestment of dividends, she directly holds 59,714 shares of Baxter common stock.
Baxter International executive Steven P. Wallace reported a small share disposition related to taxes rather than a market trade. On June 2, 2026, 153 shares of common stock were forfeited to cover tax withholding triggered by the delivery of shares from vested restricted stock units.
These restricted stock units were originally granted on June 2, 2025 and settled one year later. After this tax-withholding disposition, Wallace directly holds 70,128 shares of Baxter common stock, so the event reflects routine compensation and payroll tax handling rather than an open-market sale.
Baxter International executive James Teaff reported a small, routine share disposition tied to taxes on equity compensation. On June 2, 2026, 321 shares of common stock were forfeited at $18.68 per share to cover withholding taxes from vested restricted stock units granted on June 2, 2025. After this tax-withholding event, Teaff directly holds 31,063 shares of Baxter common stock, including shares in the company’s Employee Stock Plan.
The filing is a Form 144 notice concerning proposed sales of Common stock for BAX by an affiliate using Morgan Stanley Smith Barney LLC as broker. The record lists multiple prior open-market purchases with specific trade dates and share counts, and identifies 36,347, $645,235.58, and a reference number 516,469,008.
Baxter International Inc. adopted a new Executive Severance and Change in Control Plan effective May 4, 2026, replacing its prior executive severance program. The plan covers vice presidents and above, including Interim CFO Anita Zielinski and other named executive officers, and provides tiered cash, benefits and outplacement packages for qualifying terminations, with higher multiples and benefits if termination occurs within 24 months after a change in control.
Stockholders at the 2026 annual meeting approved increasing shares reserved under the Second Amended and Restated 2021 Incentive Plan by an additional 20,000,000 common shares and supported executive compensation and all director nominees. They also approved a charter amendment setting a minimum of seven directors, with bylaws specifying a range of seven to twelve directors.
Wilkes David S. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director David S. Wilkes received a grant of 12,836 fully vested shares of common stock. The grant was recorded at a price of $0.00 per share, reflecting a share award rather than a market purchase. Following this award and automatic reinvestment of dividends, Wilkes now directly holds a total of 37,076 Baxter common shares.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Amy McBride received a grant of 12,836 fully vested shares of common stock. The shares were awarded at no purchase price as part of her compensation and are subject to the applicable grant terms and conditions.
After this award, McBride directly holds 44,235 Baxter shares, a total that includes the automatic reinvestment of dividends. This filing reflects a compensation-related share grant rather than an open-market purchase or sale.